MET and lung cancer: Presently, EGFR-TKI resistance in lung cancer arises through various mechanisms, including secondary mutations in EGFR (e.g., T790M), activation of alternative signaling pathways (e.g., MET, HER2), phenotypic transformation (small cell transformation).